Abstract

Among the twelve catalytically active carbonic anhydrase isozymes present in the human body, the CAIX is highly overexpressed in various solid tumors. The enzyme acidifies the tumor microenvironment enabling invasion and metastatic processes. Therefore, many attempts have been made to design chemical compounds that would exhibit high affinity and selective binding to CAIX over the remaining eleven catalytically active CA isozymes to limit undesired side effects. It has been postulated that such drugs may have anticancer properties and could be used in tumor treatment. Here we have designed a series of compounds, methyl 5-sulfamoyl-benzoates, which bear a primary sulfonamide group, a well-known marker of CA inhibitors, and determined their affinities for all twelve CA isozymes. Variations of substituents on the benzenesulfonamide ring led to compound 4b, which exhibited an extremely high observed binding affinity to CAIX; the Kd was 0.12 nM. The intrinsic dissociation constant, where the binding-linked protonation reactions have been subtracted, reached 0.08 pM. The compound also exhibited more than 100-fold selectivity over the remaining CA isozymes. The X-ray crystallographic structure of compound 3b bound to CAIX showed the structural position, while several structures of compounds bound to other CA isozymes showed structural reasons for compound selectivity towards CAIX. Since this series of compounds possess physicochemical properties suitable for drugs, they may be developed for anticancer therapeutic purposes.

Highlights

  • Low-molecular-weight compounds that strongly interact and inhibit the disease target enzymes may be developed as therapeutic drugs

  • Since it has been observed that CAIX isozyme is highly overexpressed in numerous cancers, it has been postulated that compounds inhibiting CAIX may possess the anticancer activity and may be used in tumor treatment [3,4,5]

  • We have designed a series of compounds and investigated the effect of substituents and their positions in methyl halo 2- and 4-substituted-5-sulfamoyl-benzoate binding to human carbonic anhydrase (CA) isozymes

Read more

Summary

Introduction

Low-molecular-weight compounds that strongly interact and inhibit the disease target enzymes may be developed as therapeutic drugs. The carbonic anhydrase (CA) family (CA, EC 4.2.1.1), consisting of twelve catalytically active human isozymes, performs the catalysis of reversible hydration of CO2 into bicarbonate and acid protons. These enzymes participate in numerous physiological processes such as pH regulation and carbon metabolism and are related to various diseases and conditions such as glaucoma, epilepsy, cancer, edema, osteoporosis, and obesity [1,2]. We have attempted to design inhibitors with a restrained position of the ring and two functional groups attached to the benzenesulfonamide [8,9,10]. This approach helped design inhibitors selective for CAVII, CAIX, CAXII, and CAXIV

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call